Background. After the scale-up of antiretroviral therapy (ART) for human immunodeficiency virus (HIV) infection in Africa, increasing numbers of patients have pretreatment drug resistance.
Nearly 12 million people living with human immunodeficiency virus (HIV) in low-and middle-income countries received antiretroviral therapy (ART) by the end of 2013. In the context of the ambitious UNAIDS targets set for 2020 and updated treatment guidelines aiming for earlier treatment initiation, it is anticipated that increasing numbers of people will start ART in the coming years [1, 2] . The expanding exposure to antiretroviral drugs at a population level will lead to increased transmission of drug-resistant viruses [3] . As a consequence, ART programs will be confronted with increasing numbers of patients that already carry drug resistant strains before starting standard first-line ART; pretreatment drug resistance (PDR). The rise in PDR is largely attributable to an increase in nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance [3, 4] .
Previous studies from low-and middle-income [5] [6] [7] as well as high-income countries [8] have shown that individuals with PDR are at risk of a diminished virological response to first-line ART. Given the fact that in low-and middle-income countries viral load (VL) monitoring is very limited and genotypic resistance testing is largely absent, regimen switching is often guided by CD4+ cell counts and clinical criteria. This approach can lead to incorrect assumptions, risking continuation of a failing regimen on the one hand, and inappropriate switches to second-line ART (while the virus is suppressed) on the other hand [9, 10] . Even in the presence of VL monitoring, studies from Uganda and South Africa reported a delay in switching after the detection of virological failure, resulting in increased mortality relative to switching [11, 12] . Currently, access to second-line ART is restricted in many settings due to high costs; rates of switching to second-line ART have remained relatively low in resource-limited settings [13] [14] [15] .
The consequences of rising levels of PDR in sub-Saharan Africa on long-term clinical outcomes on first-line ART have not been evaluated. In a large longitudinal multi-country study, we assessed the impact of PDR on switching from first-to secondline ART due to presumed therapy failure, and the occurrence of new AIDS-events and death following up to three years of first-line ART.
METHODS

Study Design and Population
The Pan-African Studies to Evaluate Resistance Monitoring (PASER-M), a prospective cohort study at 13 clinical sites in Kenya, Nigeria, South Africa, Uganda, Zambia, and Zimbabwe [16] , enrolled patients who were HIV-1 infected, aged ≥18 years, and eligible to start first-line ART because of advanced immunodeficiency (CD4+ cell count <200 cells/µL) or HIV disease (World Health Organization [WHO] clinical stage 3 or 4) in accordance with national guidelines, between 2007 and 2009 [17] . Exclusion criteria were: pregnancy at enrolment, HIV-2 coinfection (in Nigeria), and previous use of ART ≤30 days before treatment initiation. Cohort characteristics and first year outcomes have been described previously [4, 5, 16] . For the current analysis, all participants receiving a standard first-line regimen consisting of one NNRTI drug with a dual nucleoside reverse transcriptase inhibitor (NRTI) backbone who had genotypic resistance test (GRT) results available at ART initiation were included. Participants provided written informed consent at enrolment. The study protocol was approved by national and local research ethics committees.
All participants received routine care according to local guidelines. A standard case-report form capturing data on demographics, clinical status, medication, adherence, and laboratory results was completed at enrolment, every 3 months thereafter, and at regimen switch. CD4+ cell counts recorded closest to the ART start date were used as pretreatment counts. Follow-up time was measured from ART initiation, and participants were followed up for 24 (all sites) or 36 (5 sites in Nigeria, Zimbabwe and Uganda) months on ART, or until discontinuation because of death, transfer-out, loss-to-follow-up (LTFU, when not seen for >180 days [18] ) or switch to second-line ART.
Laboratory Methods
Plasma samples were collected before ART initiation, after 12, 24, and 36 months (if applicable) and at the time of regimen switch, for retrospective testing of HIV-RNA and GRT. VL was determined using NucliSens EasyQ real-time assay (version 2.0; bioMérieux, Lyon, France) or COBAS Ampliprep/COBAS Taqman assay (Roche, Branchburg, New Jersey). Virological suppression was defined as VL < 400 cps/mL. Subsequently, GRT of protease and partial reverse-transcriptase was performed if VL ≥ 1000 cps/mL, using in-house sequencing methods. HIV drug resistance was determined in 2 steps for each sequence. First, major drug resistance mutations (DRMs) were scored using the 2014 IAS-USA list [19] . Second, the genotype susceptibility scores (GSS) of the prescribed ART regimen were calculated using the Stanford algorithm (Version 7.0) [20] . Subsequently, participants were classified in 2 categories: "PDR": presence of ≥1 DRM associated with reduced susceptibility to the prescribed regimen (GSS < 3); and "no PDR": no DRM or presence of DRMs not associated with the prescribed regimen (GSS = 3). Subtypes were determined using the REGA algorithm version 3 [21] .
Statistical Analysis
We evaluated the effect of PDR on the incidence of clinical outcomes through a time-to-event analysis. Three outcomes were defined: (I) switch to second-line ART due to presumed treatment failure; (II) onset of new AIDS events (WHO stage 4 event [2] ), that is, a first-ever event, a new condition on top of an ongoing event, or recurrence of the condition; and (III) all-cause mortality. Based on retrospective testing, unnecessary switches were defined as switch with VL < 1000 cps/mL or VL ≥ 1000 cps/mL without DRMs based on GRT [2] .
Participants were censored when transferred out, or when they received a substitution with a protease inhibitor for reasons other than treatment failure; intra-class drug substitutions were ignored. Additional censoring occurred per analysis: at switch to second-line when investigating all-cause mortality and new AIDS-events; at death for the analysis of new AIDS-events and switch to second-line. The association between PDR and the 3 outcomes was modeled through Kaplan-Meier curves with a Tarone-Ware test and univariate Cox-models, and multivariable using Cox-models with age and sex as fixedcovariates, and CD4+ cell count and 30-day self-reported adherence (visual analogue score <95% or ≥95%) as time-varying covariates. Standard errors were adjusted for clustering within clinical site. The following fixed-variables were considered confounders and included in the model if ≥10% changes in the regression coefficient describing the association between PDR and all four outcomes: WHO clinical stage at baseline (1-3 vs 4), prior antiretroviral drug exposure (yes, no, unknown), year of ART initiation (2007, 2008, 2009 ), hemoglobin at baseline, and subtype (C, non-C). The proportional-hazard assumption was checked using log-log plots and testing the Schoenfeld residuals.
Sensitivity Analyses
First, we repeated the analyses using more specific outcomes: HIV-related mortality instead of all-cause mortality and "appropriate switches" (VL ≥ 1000 cps/mL and ≥1 DRM) instead of any switch. Second, we repeated the analyses for all sites up to 24 months, vs the 5 sites who had follow-up data available up to 36 months. Third, we repeated the analyses, only for participants who were antiretroviral drug-naive, excluding those who had any prior antiretroviral drug exposure. All analyses were performed using Stata 12 [22] .
RESULTS
Of the 2737 participants initiating ART, 2579 (94.2%) had GRT results available and were included in our analysis ( Figure 1 , Table 1 ). In total, 357 (13.8%) had DRMs: 297 (11.5%) had NNRTI-mutations, 69 (2.7%) had NRTI-mutations, and 37 (1.4%) had dual-class resistance. Overall, 141/2579 (5.5%) participants were classified as having PDR. All pretreatment DRMs are listed in the Supplementary Material. After 12 and 24 months respectively, 83.4% and 72.2% of patients were still alive, retained in care and receiving first-line ART. In Nigeria, Uganda, and Zimbabwe, 64.6% of participants were still alive and retained on first-line ART after 36 months (Figure 1 ). LTFU was equal in participants with and without PDR. Most participants remained on the initial regimen; 728 (28.3%) received at least 1 drug substitution for reasons other than treatment failure (range 1-4); protease inhibitor-substitutions for reasons other than treatment failure occurred in 55 (0.02%) participants who were subsequently censored.
Virological suppression was achieved in 89.8% (95% confidence interval [CI], 88.4-91.1), 89.8% (95% CI, 88.3-91.2), and 90.7% (95% CI, 88.1-92.8) of participants retained in care at 12, 24, and 36 months, respectively. Suppression rates were significantly lower in people with vs those without PDR: . In adjusted analysis, PDR was strongly associated with switching to second-line: adjusted hazard ratio (aHR) 3.80 (95% CI, 1.49-9.68; P = .005, Table 3 and Figure 2) .
Overall, clinicians reported using VL testing to confirm treatment failure for 75/106 (70.8%) switches, and clinical and/or immunological criteria for 23/106 (21.7%). For 8/106 (7.5%) 
New AIDS-event(s)
Overall, 182 new AIDS-events were observed, with a rate of 39.1 (95% CI, 33.8-45.2) new events per 1000 person-years (Supplementary Material). The events were mainly extra-pulmonary tuberculosis (26.1%), HIV wasting (24.1%), chronic herpes simplex infection (12.3%), and esophageal candidiasis (8.4%) and are specified in the Supplementary Material. The incidence of AIDS-events did not differ significantly between participants with and without PDR in both unadjusted (Tarone-Ware P = .7380; Cox P = .822) and adjusted (aHR 1.06, 95% CI, .68-1.64; P = .807) analysis (Table 3 and Figure 2 ).
All-cause Mortality
Overall, 188 (7.3%) persons died during follow-up; the mortalityrate was 38.6 (95% CI, 33.4-44.5) per 1000 person-years and varied over time (Supplementary Material). Ninety-seven (51.6%) died <90 days of treatment with a rate of 436.1 (95% CI, 357.4-532.1) per 1000 person-years. All-cause mortality was not significantly different for participants with or without PDR, both in the unadjusted (Tarone-Ware P = .5746; Cox P = .642) and adjusted (aHR 0.75, 95% CI, .24-2.35; P = .617) analysis (Table 3 and Figure 2 ). The majority of deaths were reported to be HIV-related (N = 125, 66.5%); 7 (3.7%) were reported to be not HIV-related and for 56 (29.8%) the cause of death was unknown. Sensitivity analysis of confirmed HIV-related mortality yielded similar results (Supplementary Material). Both sensitivity analyses excluding participants with previous antiretroviral drug use, and exploring different follow-up at the sites yielded similar results for all 3 outcomes (Supplementary Material).
DISCUSSION
In this large prospective study in sub-Saharan Africa, we demonstrated that participants harboring drug-resistant HIV before starting standard first-line ART (ie, PDR) resulted in a nearly 4-fold increase of switches to second-line ART. During the first 3 years of ART, PDR was not associated with new AIDSrelated events or excess mortality. Our findings remained robust in several sensitivity analyses. To our knowledge, this is the first study that provides direct evidence that the rise in PDR levels Abbreviations: CI, confidence interval; HR, hazard ratio; PDR, pretreatment drug resistance. a Adjusted model: Adjusted for sex and age (fixed), CD4+ cell count and adherence (time-varying), clustered for site. All-cause mortality and switches were also adjusted for previous antiretroviral use. b Switches due to presumed treatment failure.
after the ART scale-up in Africa will drive a significant growth in the demand for second-line ART in the region. This emerging threat to the effectiveness of national ART programs will have major public health implications in terms of budget requirements and program planning in the coming years. There is a critical need for the scale-up of second-line ART, which calls for augmented resources and training for clinicians. This study found no significant differences in incidence of AIDS-events and mortality during the first three years on first-line ART among participants with PDR compared to those without. Although several studies have reported that PDR predicts a poor virological response to ART [5, 7, 8] , the continuation of a failing regimen may still provide some clinical and immunological benefit because of residual drug activity and the reduced fitness of the mutant virus [23] . Nonetheless, it is possible that the impact of PDR on the development of new AIDS-events and mortality will only become manifest on the long term, that is, >3 years of ART [24] .
In our cohort, we documented an overall PDR prevalence of 5.5% in sub-Saharan Africa in 2007-2009. The most comprehensive global assessment to date suggested a significant increase in PDR over time since ART rollout, at an estimated annual rate of 29% for east Africa and 14% for southern Africa. The rise is driven by NNRTI-resistance, which is of particular concern as this drug class constitutes the foundation of current first-line ART regimens and prophylaxis for prevention of mother-to-child transmission. A mathematical model based on combined data on transmitted and acquired drug resistance from Kampala, Uganda, and Mombasa, Kenya, predicted that the continued ART scale-up may lead to increased prevalence of PDR in the coming 10 years, up to 19% [25] .
Of note, the same model projected that future levels of NNRTI resistance could be diminished through better switching practices. By means of enhanced implementation of VL monitoring, accurate switching to second-line therapy can improve patient outcomes and reduce drug resistance [25, 26] . In the light of these trends, our data point toward substantial increases in the need for second-line antiretroviral drugs in the coming years. Increased use of second-line drugs could in turn enhance long-term treatment success and curb the emergence of drug-resistant HIV [25] [26] [27] .
The switch rate in our study of 21.8 per 1000 person-years (95% CI, 18.0-26.3) was in line with the IeDEA cohort that reported 24 switches per 1000 person-years (95% CI, [22] [23] [24] [25] [26] [28] . By contrast, switch rates previously reported in MSF-run ART programs were much lower with 4.2 switches per 1000 personyears. The difference is possibly attributable to limited access to VL monitoring in the latter study [29] . In a recent meta-analysis of first-line ART outcomes, the current rate of switch to secondline in resource-limited settings was low, that is, <2% during the first 2 years on ART [15] . Long-term switch rates were estimated at 5.4% (95% CI, 3.3-7.5) and 9.2% (95% CI, 4.8-13.6) after 3 and 4 years, respectively [15] . Barriers for switching are the low availability of second-line drugs (including drug stock-outs), lack of virological monitoring, limited physician training and experience with switching, and reluctance to shift to the last available treatment option in low-resource settings [28, 30, 31] .
Of concern, 24% of participant in this study who were switched to second-line ART either had VL < 1000 cps/mL, or VL ≥ 1000 cps/mL without presence of DRMs, which means they could still have benefited from continuing on first-line ART. Unnecessary switching to more costly and toxic secondline ART, as reported in previous studies [10] , impairs the efficiency in the use of scarce resources available in ART programs. Moreover, previous studies from Africa suggested that a considerable proportion of patients with detectable viremia can (re-)suppress on their first-line ART after adherence counselling [10, 32] . These findings support the current WHO recommendation that patients who have suspected virological failure should receive adherence counselling and a repeat VL test for confirmation of failure before considering a regimen switch [2] . Thus, increased access and uptake of available VL testing can avert unnecessary switches to second-line therapy [10] .
Although VL monitoring is the preferred monitoring tool to diagnose and confirm treatment failure, access to VL testing followed by regimen switching remains challenging and costly [12, 33] . Given the fact that second-line regimens are currently at least 2.4 times more expensive than first-line ART (and thirdline regimens 15 times), increased switching will inevitably lead to substantial increased expenditures of HIV treatment in the region [34, 35] . These expenditures will have to compete for resources for (first-line) ART scale-up. Mathematical modelling studies and economic analyses have evaluated different treatment monitoring strategies, and yielded conflicting results [26, 36, 37] . Cost-effectiveness, however, will improve as more affordable VL testing techniques (using dried blood spots) become available in resource-limited settings [27, 37, 38] . Furthermore, further price reductions of second-line drugs ( protease inhibitors) will reduce treatment costs. Although the largest clinical benefit is expected to be achieved by VL monitoring, individual GRT after first-line failure might increase appropriate switching, and recent studies from South Africa have indicated that it is potentially cost effective in middle-income countries [27, 39, 40] .
The main strengths of the study were its large size, longitudinal design with long-term follow-up, and the setting of large-scale, routine ART programs, which enhance the generalizability of the results. The reported attrition rates, including high early mortality, were substantial but in line with other studies from sub-Saharan Africa [41] [42] [43] . Our study adds to the current knowledge that the increase in PDR will necessitate expanded access to VL monitoring and second-line ART in order to sustain effective long-term HIV treatment in Africa [2, 28] . Further studies and mathematical modeling are needed to establish optimum strategies for the prevention of HIV drug resistance, the role of pre-ART genotyping, and use of protease-inhibitorbased regimens for specific high-risk groups.
This study has some potential limitations. Although the PASER network includes mostly free-access, routine ART programs, nongovernment and urban sites were over-represented and rural sites under-represented. Therefore, caution is warranted when extrapolating results to other settings where resource constraints might be even more substantial [16] . Second, participants LTFU may have introduced bias, but LTFU was equal among participants with and without PDR [44] . Third, there is potential for attrition bias because differential follow-up duration across the sites. Sensitivity analyses showed that such bias is expected to be limited. Last, population-based sequencing is not able to detect minority drug resistance; therefore, participants who had minority resistant strains could have been classified as having a "no PDR," resulting in a potential underestimation of the effect of PDR on treatment outcomes.
In conclusion, our findings demonstrate that the presence of PDR diminishes the long-term effectiveness of first-line ART and is strongly associated with switching to second-line regimens. In view of rising PDR levels in Africa, these findings underscore the urgent need for increased implementation of VL monitoring and access to affordable second-line regimens to secure durable ART success in sub-Saharan Africa.
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